Small cell lung cancer recurrent

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Monoclonal antibody (rat) 1 substance
Phase III: 1 Phase II: 2 Phase I: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial

Phase II

2 trials
  • Amgen Inc. Commercial
    TARLATAMAB
    2024-511837-37-00 9 countries 2021 n=113 Orphan
    Ended
  • AIO-Studien gGmbH Academic
    TARLATAMAB
    2025-522437-65-00 1 country 2026 n=57
    Recruiting

Phase I

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2024-513625-23-00 1 country 2021 n=1
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 2 Phase II, Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 0
AIO-Studien gGmbH Academic 1 Phase II 1
New trials by year
2021
2
2023
1
2026
1
← All indication landscapes